Tag: CMT2E

CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E

The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28 that it has approved a $225,483 award to Dr. Mario Saporta at the University of Miami for a study on the use of antisense oligonucleotides (ASOs) to treat CMT2E. CMT is one of the most commonly inherited peripheral neuropathies, affecting…

Continue Reading CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E

NFL Biomarker Unsuitable to Measure CMT1A Outcomes, Study Shows

Blood levels of the protein neurofilament light chain (NFL), a biomarker of several neurological disorders, may not be suitable to measure outcomes in patients with Charcot-Marie-Tooth disease type 1A (CMT1A), a recent study suggests. The study, “A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease,”…

Continue Reading NFL Biomarker Unsuitable to Measure CMT1A Outcomes, Study Shows

CMT2 Research Projects Launched by CMTA Seed Money Win NIH Funds

Two research projects focused on developing gene-editing therapies for Charcot-Marie-Tooth disease type 2 (CMT2) — both launched with seed monies from the Charcot-Marie-Tooth Association-Strategy to Accelerate Research (CMTA-STAR) program — have now been awarded additional funding from the National Institutes of Health (NIH). According to a CMTA press release, these NIH…

Continue Reading CMT2 Research Projects Launched by CMTA Seed Money Win NIH Funds